- Maximum standardized uptake value (SUVmax) measured from pretreatment positron emission tomography (PET) scans predicts response to specific frontline therapies for advanced-stage follicular lymphoma.
Why this matters
- PET-based imaging has improved cancer staging and histological classification, but its prognostic value is unclear.
- Researchers analyzed health records of patients with advanced-stage FL without histological evidence of transformation (N=346; 55% men; median SUVmax, 11 [range, 1.5-42]).
- Primary outcome: frontline treatment outcomes with SUVmax >18 (15%) vs ≤18.
- Regimens included nonanthracycline-based regimens and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
- Funding: MD Anderson Cancer Center.
- With SUVmax >18, complete response rates were lower with nonanthracycline-based regimens (45% vs 92%; P<.001 but not>
- Data also showed shorter PFS with nonanthracycline-based regimens (77 months vs not reached; P=.02), but not R-CHOP (P=.73).
- Patients with SUVmax >18 had shorter 8-year OS with nonanthracycline-based regimens (50% vs 85%; P=.001) and R-CHOP (70% vs 90%; P=.02).
- The study was retrospective and did not account for total metabolic tumor volume.